Last reviewed · How we verify
CM338 Injection
CM338 Injection is a monoclonal antibody targeting the PD-1 receptor.
CM338 Injection is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | CM338 Injection |
|---|---|
| Sponsor | Keymed Biosciences Co.Ltd |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to PD-1, CM338 Injection prevents the interaction between PD-1 and its ligands, thereby releasing the brakes on the immune system and enhancing anti-tumor activity. This mechanism is thought to be particularly effective in treating various types of cancer.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
Key clinical trials
- Single Ascending Dose Study of CM338 in Healthy Volunteers (PHASE1)
- Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy (PHASE2)
- Multiple Ascending Dose Study of CM338 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CM338 Injection CI brief — competitive landscape report
- CM338 Injection updates RSS · CI watch RSS
- Keymed Biosciences Co.Ltd portfolio CI